CNDA approves first PARP inhibitor Lipdro ® (Olapari tablet) for maintenance therapy for recurrent ovarian cancer

over the past 10 years, the incidence of ovarian cancer in China has increased by 30 per cent and the mortality rate by 18 per centHowever, ovarian cancer had the lowest 5-year survival rate in gynecological malignancies, only 39%, and the highest recurrence rate in 5 years, reaching 70%Due to the lack of effective screening methods and the near absence of specific symptoms, it is difficult to detect and diagnose early, so more than 70% of patients are late at the time of diagnosisrecently, AstraZeneca China and Mersa East China jointly announced that China's NationalDrug(CNDA) has approved the first PARP inhibitor, the Liptro® (Olapari tablet) for the maintenance treatment of platinum-sensitive recurrent ovarian cancerabout Lipdro® (Olapari)Lipdro® (Olapari) is the first oral polypolyadp anucleopolymer (PARP) inhibitor to kill tumor cells by inhibiting PARP enzyme activity and preventing PARP and DNA disconnection, in collaboration with DNA damage repair defects"Targeted to block" the DNA repair pathway of tumor cells, killing cancer cells from the "source."currently, Olapari can be used in the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients in China, whether or not they carry a BRCA mutationin the clinical study SOLO-2, it was found that patients with BRCA germ-mutated platinum-sensitive recurrent ovarian cancer were treated with Olapari tablets (twice a day), and THAT PFS (no progression survival) was significantly extended to 19.1 months, with a small toxic side effectThe Study19 study confirmed the efficacy of PARP inhibitors against platinum-sensitive recurrent ovarian cancer, with PFS (no progression survival) nearly 2 times longer in the group of patients with Olapari compared to placebo patients (4.8 months in the Olapari group 8.4 months VS placebo group), and a 65 percent reduction in the risk of disease progression or deathAstraZeneca and Mersadon have reached a strategic partnership for cancer, and the two sides will jointly develop and commercializenew drugsuch as Liptron ®